| Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation. | | Saito K, Fujiwara T, Hatta S, Morita M, Ono K, Suzuki C, Fukuhara N, Onishi Y, Nakamura Y, Kawamata S, Shimizu R, Yamamoto M, Harigae H. | Mol Cell Biol. 39, pii: e00387-18. (2019) | | |
| | | |
| Nrf2 Suppresses Allergic Lung Inflammation by Attenuating the Type 2 Innate Lymphoid Cell Response. | | Nagashima R, Kosai H, Masuo M, Izumiyama K, Noshikawaji T, Morimoto M, Kumaki S, Miyazaki Y, Motohashi H, Yamamoto M, Tanaka N. | J Immunol. 202, 1331-1339 (2019) | | |
| | | |
| Nrf2 deficiency aggravates the increase in osteoclastogenesis and bone loss induced by inorganic arsenic. | | Liu Z, Hou Y, Li L, Yang Y, Jia J, Hong Z, Li T, Xu Y, Fu J, Sun Y, Yamamoto M, Wang H, Pi J. | Toxicol Appl Pharmacol. 367, 62-70 (2019) | | |
| | | |
| Sulforaphane enriched transcriptome of lung mitochondrial energy metabolism and provided pulmonary injury protection via Nrf2 in mice. | | Cho HY, Miller-DeGraff L, Blankenship-Paris T, Wang X, Bell DA, Lih F, Deterding L, Panduri V, Morgan DL, Yamamoto M, Reddy AJ, Talalay P, Kleeberger SR. | Toxicol Appl Pharmacol. 364, 29-44 (2019) | | |
| | | |
| Spiral ganglion cell degeneration-induced deafness as a consequence of reduced GATA factor activity. | | Hoshino T, Terunuma T, Takai J, Uemura S, Nakamura Y, Hamada M, Takahashi S, Yamamoto M, Engel JD, Moriguchi T. | Genes Cells. 24, 534-545 (2019) | | |
| | | |
| Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension-High-throughput Screening of 5,562 Compounds. | | Kurosawa R, Satoh K, Kikuchi N, Kikuchi H, Saigusa D, Al-Mamun EA, Siddique MAH, Omura J, Satoh T, Sunamura S, Nogi M, Numano K, Miyata S, Uruno A, Kano K, Matsumoto Y, Doi T, Aoki J, Oshima Y, Yamamoto M, Shimokawa H. | Circ Res. 125, 309-327 (2019) | | |
| | | |
| Estimating carrier frequencies of newborn screening disorders using a whole-genome reference panel of 3552 Japanese individuals. | | Yamaguchi-Kabata Y, Yasuda J, Uruno A, Shimokawa K, Koshiba S, Suzuki Y, Fuse N, Kawame H, Tadaka S, Nagasaki M, Kojima K, Katsuoka F, Kumada K, Tanabe O, Tamiya G, Yaegashi N, Kinoshita K, Yamamoto M, Kure S; Tohoku Medical Megabank Project Study Group. | Hum Genet. 138, 389-409 (2019) | | |
| | | |
| Molecular Mechanism of Cellular Oxidative Stress Sensing by Keap1. | | Suzuki T, Muramatsu A, Saito R, Iso T, Shibata T, Kuwata K, Kawaguchi SI, Iwawaki T, Adachi S, Suda H, Morita M, Uchida K, Baird L, Yamamoto M. | Cell Rep. 28, 746-758 (2019) | 鈴木隆史講師、大学院生の村松さんの論文です | |
| | | |
| Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function. | | Nagasu H, Sogawa Y, Kidokoro K, Itano S, Yamamoto T, Satoh M, Sasaki T, Suzuki T, Yamamoto M, Wigley WC, Proksch JW, Meyer CJ, Kashihara N. | FASEB J. 33, 12253-12263 (2019) | | |
| | | |
|
Publications 2019 